Efficacy of newly discovered DNA aptamers targeting AXL in a lung cancer cell with acquired resistance to Erlotinib.

Hwang, Ji An; Hur, Jae Young; Kim, Youndong; Im, Jong Hun; Jin, Seong Hui; Ryu, Sung Ho; Choi, Chang-Min

Hwang, Ji An; Hur, Jae Young; Kim, Youndong; Im, Jong Hun; Jin, Seong Hui; Ryu, Sung Ho; Choi, Chang-Min.

Afiliación

Hwang JA; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hur JY; Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim Y; Precision Medicine Lung Cancer Center, Konkuk University Medical Center, Seoul, Korea.
Im JH; Department of Pathology, Konkuk University Medical Center, Seoul, Korea.
Jin SH; Aptamer Sciences Inc., Pohang, Korea.
Ryu SH; Aptamer Initiative, POSTECH Biotech Center, POSTECH, Pohang, Korea.
Choi CM; Aptamer Initiative, POSTECH Biotech Center, POSTECH, Pohang, Korea.

Transl Cancer Res ; 10(2): 1025-1033, 2021 Feb.

Article en En | MEDLINE | ID: mdl-35116429

Palabras clave

AXL; DNA aptamer; acquired resistance; epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI); lung cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Transl Cancer Res Año: 2021 Tipo del documento: Article